{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:00:13Z","timestamp":1781629213440,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Patient derived xenografts (PDXs) are widely used in preclinical research. However, lymphoproliferative \u2018outgrowths\u2019 at the site of tumour xenoplantation are a common source of failure in the creation of the disease model. In this work, we assessed the performance of 10-second molecular profiling of xenoplanted tissue with picosecond infrared laser mass spectrometry (PIRL-MS) as a new method for rapid identification of lymphoproliferative \u2018outgrowths\u2019 in serial passages to streamline the quality control workflow. PIRL-MS can identify \u2018imposter\u2019 lymphoproliferative tumours with sensitivity and specificity values of &gt;\u200999%. This observation is established over\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009258 independent PDX specimens and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093,393 ten-second mass spectral data points used for building and validating (blind assessment) a classifier multivariate model to enable discrimination. We first established a classifier model based on principal component analysis coupled with linear discriminant analysis (PCA-LDA) to discriminate between true solid tumour PDXs (of 5 common epithelioid cancer types originating from lung, pancreas, ovarian, colon and head &amp; neck as well as imposter tumours of lymphoproliferative origin. Implementation of the classifier only requires 10 seconds of mass spectral data collection (using a hand-held probe) and less than an additional second for data processing and evaluation against the model towards a classification. In addition, PIRL-MS analysis does not require any tissue preparation before analysis, and from previous research can also be deployed\n                    <jats:italic>in situ\/in vivo<\/jats:italic>\n                    to save time. These attributes, coupled with its reported high sensitivity and specificity for identification of imposter lymphoproliferative tumours, position PIRL-MS as a rapid quality control method for fidelity assessment of xenoplanted tissues. These observations motivate follow-on work to reduce the cost and the footprint of the PIRL-MS platform towards lowering the adoption barrier for routine use.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-33064-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:37:43Z","timestamp":1767789463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Picosecond infrared laser mass spectrometry for 10-second identification of lymphoproliferative imposter tumours in patient-derived xenografts"],"prefix":"10.1038","volume":"16","author":[{"given":"Lan-Anna","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darah","family":"Vlaminck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Fiorante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu G.","family":"Dabija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Froment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhareth","family":"Azaizeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinjiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani","family":"Shouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Shouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Sound","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Ailles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu-An","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Zarrine-Afsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"33064_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi, S. et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J. Transl Med. 20, 206. https:\/\/doi.org\/10.1186\/s12967-022-03405-8 (2022).","journal-title":"J. Transl Med."},{"key":"33064_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-019-0829-z","volume":"13","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida, G. J. Applications of patient-derived tumor xenograft models and tumor organoids. J. Hematol. Oncol. 13, 4. https:\/\/doi.org\/10.1186\/s13045-019-0829-z (2020).","journal-title":"J. Hematol. Oncol."},{"key":"33064_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal. Transduct. Target. Ther. 8, 160. https:\/\/doi.org\/10.1038\/s41392-023-01419-2 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"33064_CR4","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3390\/cells8080889","volume":"8","author":"S. Okada","year":"2019","unstructured":"Okada, S., Vaeteewoottacharn, K. & Kariya, R. Application of highly immunocompromised mice for the establishment of patient-derived xenograft (PDX) models. Cells 8, 889 https:\/\/doi.org\/10.3390\/cells8080889 (2019).","journal-title":"Cells"},{"key":"33064_CR5","doi-asserted-by":"publisher","first-page":"e70059","DOI":"10.1002\/mco2.70059","volume":"6","author":"A Gu","year":"2025","unstructured":"Gu, A., Li, J., Li, M. Y. & Liu, Y. Patient-derived xenograft model in cancer: Establishment and applications. MedComm 6, e70059. https:\/\/doi.org\/10.1002\/mco2.70059 (2025).","journal-title":"MedComm"},{"key":"33064_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-0716-3858-3_2","volume":"2806","author":"S Aslani","year":"2024","unstructured":"Aslani, S. & Saad, M. I. Patient-Derived xenograft models in cancer research: Methodology, applications, and future prospects. Methods Mol. Biol. 2806, 9\u201318. https:\/\/doi.org\/10.1007\/978-1-0716-3858-3_2 (2024).","journal-title":"Methods Mol. Biol."},{"key":"33064_CR7","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ame2.12349","volume":"6","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. Progress in Building clinically relevant patient-derived tumor xenograft models for cancer research. Anim. Model. Exp. Med. 6, 381\u2013398. https:\/\/doi.org\/10.1002\/ame2.12349 (2023).","journal-title":"Anim. Model. Exp. Med."},{"key":"33064_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ol.2018.9583","volume":"17","author":"C Xu","year":"2019","unstructured":"Xu, C., Li, X., Liu, P., Li, M. & Luo, F. Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine. Oncol. Lett. 17, 3\u201310. https:\/\/doi.org\/10.3892\/ol.2018.9583 (2019).","journal-title":"Oncol. Lett."},{"key":"33064_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/JTO.0b013e3182519d4d","volume":"7","author":"T John","year":"2012","unstructured":"John, T. et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J. Thorac. Oncol. 7, 1101\u20131108. https:\/\/doi.org\/10.1097\/JTO.0b013e3182519d4d (2012).","journal-title":"J. Thorac. Oncol."},{"key":"33064_CR10","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.3892\/or.2018.6769","volume":"40","author":"K Kalavska","year":"2018","unstructured":"Kalavska, K. et al. Lymphoma transformation of tumor infiltrating lymphocytes observed in testicular patient\u2013derived xenograft models. Oncol. Rep. 40, 3593\u20133602. https:\/\/doi.org\/10.3892\/or.2018.6769 (2018).","journal-title":"Oncol. Rep."},{"key":"33064_CR11","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jpedsurg.2018.10.051","volume":"54","author":"AP Williams","year":"2019","unstructured":"Williams, A. P. et al. Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma. J. Pediatr. Surg. 54, 2117\u20132119. https:\/\/doi.org\/10.1016\/j.jpedsurg.2018.10.051 (2019).","journal-title":"J. Pediatr. Surg."},{"key":"33064_CR12","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1002\/ijc.30561","volume":"140","author":"SM Dieter","year":"2017","unstructured":"Dieter, S. M. et al. Patient-derived xenografts of Gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. Int. J. Cancer. 140, 1356\u20131363. https:\/\/doi.org\/10.1002\/ijc.30561 (2017).","journal-title":"Int. J. Cancer"},{"key":"33064_CR13","doi-asserted-by":"publisher","first-page":"1156743","DOI":"10.3389\/fonc.2023.1156743","volume":"13","author":"DR Pearce","year":"2023","unstructured":"Pearce, D. R. et al. Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer. Front. Oncol. 13, 1156743. https:\/\/doi.org\/10.3389\/fonc.2023.1156743 (2023).","journal-title":"Front. Oncol."},{"key":"33064_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.neo.2015.09.004","volume":"17","author":"G Bondarenko","year":"2015","unstructured":"Bondarenko, G. et al. Patient-Derived tumor xenografts are susceptible to formation of human lymphocytic tumors. Neoplasia 17, 735\u2013741. https:\/\/doi.org\/10.1016\/j.neo.2015.09.004 (2015).","journal-title":"Neoplasia"},{"key":"33064_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/pros.22939","volume":"75","author":"C Wetterauer","year":"2015","unstructured":"Wetterauer, C. et al. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate 75, 585\u2013592. https:\/\/doi.org\/10.1002\/pros.22939 (2015).","journal-title":"Prostate"},{"key":"33064_CR16","doi-asserted-by":"publisher","first-page":"e39294","DOI":"10.1371\/journal.pone.0039294","volume":"7","author":"K Chen","year":"2012","unstructured":"Chen, K., Ahmed, S., Adeyi, O., Dick, J. E. & Ghanekar, A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One. 7, e39294. https:\/\/doi.org\/10.1371\/journal.pone.0039294 (2012).","journal-title":"PLoS One"},{"key":"33064_CR17","doi-asserted-by":"publisher","first-page":"e0188228","DOI":"10.1371\/journal.pone.0188228","volume":"12","author":"AJ Taurozzi","year":"2017","unstructured":"Taurozzi, A. J. et al. Spontaneous development of Epstein-Barr virus associated human lymphomas in a prostate cancer xenograft program. PLoS One. 12, e0188228. https:\/\/doi.org\/10.1371\/journal.pone.0188228 (2017).","journal-title":"PLoS One"},{"key":"33064_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s11307-024-01917-x","volume":"26","author":"S Shmuel","year":"2024","unstructured":"Shmuel, S., Monette, S., Ibrahim, D. & Pereira, P. M. R. PDX models in theranostic applications: generation and screening for B cell lymphoma of human origin. Mol. Imaging Biol. 26, 569\u2013576. https:\/\/doi.org\/10.1007\/s11307-024-01917-x (2024).","journal-title":"Mol. Imaging Biol."},{"key":"33064_CR19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.neo.2018.02.003","volume":"20","author":"S Corso","year":"2018","unstructured":"Corso, S. et al. Rituximab treatment prevents lymphoma onset in gastric cancer Patient-Derived xenografts. Neoplasia 20, 443\u2013455. https:\/\/doi.org\/10.1016\/j.neo.2018.02.003 (2018).","journal-title":"Neoplasia"},{"key":"33064_CR20","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.tranon.2021.101133","volume":"14","author":"S Chateau-Joubert","year":"2021","unstructured":"Chateau-Joubert, S. et al. Spontaneous mouse lymphoma in patient-derived tumor xenografts: the importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials. Transl Oncol. 14, 101133. https:\/\/doi.org\/10.1016\/j.tranon.2021.101133 (2021).","journal-title":"Transl Oncol."},{"key":"33064_CR21","first-page":"198","volume":"42","author":"SM Baird","year":"1982","unstructured":"Baird, S. M. et al. Induction of lymphoma in antigenically stimulated athymic mice. Cancer Res. 42, 198\u2013206 (1982).","journal-title":"Cancer Res."},{"key":"33064_CR22","doi-asserted-by":"publisher","first-page":"9447","DOI":"10.1038\/srep09447","volume":"5","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. Sci. Rep. 5, 9447. https:\/\/doi.org\/10.1038\/srep09447 (2015).","journal-title":"Sci. Rep."},{"key":"33064_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998\u20131013. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0001 (2014).","journal-title":"Cancer Discov"},{"key":"33064_CR24","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41598-017-00272-y","volume":"7","author":"M Woolman","year":"2017","unstructured":"Woolman, M. et al. Optimized mass spectrometry analysis workflow with polarimetric guidance for ex vivo and in situ sampling of biological tissues. Sci. Rep. 7, 468. https:\/\/doi.org\/10.1038\/s41598-017-00272-y (2017).","journal-title":"Sci. Rep."},{"key":"33064_CR25","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1158\/0008-5472.CAN-18-3411","volume":"79","author":"M Woolman","year":"2019","unstructured":"Woolman, M. et al. Picosecond infrared laser desorption mass spectrometry identifies Medulloblastoma subgroups on intrasurgical timescales. Cancer Res. 79, 2426\u20132434. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3411 (2019).","journal-title":"Cancer Res."},{"key":"33064_CR26","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1021\/acs.analchem.3c03156","volume":"96","author":"M Woolman","year":"2024","unstructured":"Woolman, M. et al. Lipidomic-Based approach to 10 s classification of major pediatric brain cancer types with picosecond infrared laser mass spectrometry. Anal. Chem. 96, 1019\u20131028. https:\/\/doi.org\/10.1021\/acs.analchem.3c03156 (2024).","journal-title":"Anal. Chem."},{"key":"33064_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf047","author":"A Fiorante","year":"2025","unstructured":"Fiorante, A. et al. A molecular array for 10-second diagnosis of common spinal tumour types with picosecond infrared laser mass spectrometry. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf047 (2025).","journal-title":"Neuro Oncol."},{"key":"33064_CR28","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.3390\/ijms25063491","volume":"25","author":"A Fiorante","year":"2024","unstructured":"Fiorante, A. et al. A workflow for meaningful interpretation of classification results from handheld ambient mass spectrometry analysis probes. Int. J. Mol. Sci. 25, 3491 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"33064_CR29","doi-asserted-by":"publisher","first-page":"16821","DOI":"10.1021\/acs.analchem.2c03918","volume":"94","author":"L Katz","year":"2022","unstructured":"Katz, L. et al. Picosecond infrared laser mass spectrometry identifies a metabolite array for 10 s diagnosis of select skin cancer types: A Proof-of-Concept feasibility study. Anal. Chem. 94, 16821\u201316830. https:\/\/doi.org\/10.1021\/acs.analchem.2c03918 (2022).","journal-title":"Anal. Chem."},{"key":"33064_CR30","doi-asserted-by":"publisher","first-page":"14430","DOI":"10.1021\/acs.analchem.3c02901","volume":"95","author":"L Katz","year":"2023","unstructured":"Katz, L. et al. Metabolic lipids in melanoma enable rapid determination of actionable BRAF-V600E mutation with picosecond infrared laser mass spectrometry in 10 s. Anal. Chem. 95, 14430\u201314439. https:\/\/doi.org\/10.1021\/acs.analchem.3c02901 (2023).","journal-title":"Anal. Chem."},{"key":"33064_CR31","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1039\/c7sc01974b","volume":"8","author":"M Woolman","year":"2017","unstructured":"Woolman, M. et al. Rapid determination of Medulloblastoma subgroup affiliation with mass spectrometry using a handheld picosecond infrared laser desorption probe. Chem. Sci. 8, 6508\u20136519. https:\/\/doi.org\/10.1039\/c7sc01974b (2017).","journal-title":"Chem. Sci."},{"key":"33064_CR32","doi-asserted-by":"publisher","first-page":"8723","DOI":"10.1039\/d0sc02241a","volume":"11","author":"M Woolman","year":"2020","unstructured":"Woolman, M. et al. In situ tissue pathology from spatially encoded mass spectrometry classifiers visualized in real time through augmented reality. Chem. Sci. 11, 8723\u20138735. https:\/\/doi.org\/10.1039\/d0sc02241a (2020).","journal-title":"Chem. Sci."},{"key":"33064_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12917-020-02451-y","volume":"16","author":"Percie du Sert","year":"2020","unstructured":"Percie du Sert. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMC Vet. Res. 16, 242. https:\/\/doi.org\/10.1186\/s12917-020-02451-y (2020).","journal-title":"BMC Vet. Res."},{"key":"33064_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13361-017-1818-5","volume":"29","author":"Z Bodai","year":"2018","unstructured":"Bodai, Z. et al. Effect of electrode geometry on the classification performance of rapid evaporative ionization mass spectrometric (REIMS) bacterial identification. J. Am. Soc. Mass. Spectrom. 29, 26\u201333. https:\/\/doi.org\/10.1007\/s13361-017-1818-5 (2018).","journal-title":"J. Am. Soc. Mass. Spectrom."},{"key":"33064_CR35","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1080\/03610920008832559","volume":"29","author":"M Geun Kim","year":"2000","unstructured":"Geun Kim, M. Multivariate outliers and decompositions of Mahalanobis distance. Commun. Stat. - Theory Methods. 29, 1511\u20131526. https:\/\/doi.org\/10.1080\/03610920008832559 (2000).","journal-title":"Commun. Stat. - Theory Methods"},{"key":"33064_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/978-3-030-65768-0_3","volume":"1311","author":"JK Park","year":"2021","unstructured":"Park, J. K., Coffey, N. J., Limoges, A. & Le, A. The heterogeneity of lipid metabolism in cancer. Adv. Exp. Med. Biol. 1311, 39\u201356. https:\/\/doi.org\/10.1007\/978-3-030-65768-0_3 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"33064_CR37","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","volume":"279","author":"CR Santos","year":"2012","unstructured":"Santos, C. R. & Schulze, A. Lipid metabolism in cancer. FEBS J. 279, 2610\u20132623. https:\/\/doi.org\/10.1111\/j.1742-4658.2012.08644.x (2012).","journal-title":"FEBS J."},{"key":"33064_CR38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/metabo11100660","volume":"11","author":"L. Katz","year":"2021","unstructured":"Katz, L., Tata, A., Woolman, M. & Zarrine-Afsar, A. Lipid profiling in cancer diagnosis with hand-held ambient mass spectrometry probes: Addressing the late-stage performance concerns. Metabolites 11, 660 https:\/\/doi.org\/10.3390\/metabo11100660 (2021).","journal-title":"Metabolites"},{"key":"33064_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cll.2021.03.004","volume":"41","author":"M Woolman","year":"2021","unstructured":"Woolman, M., Katz, L., Tata, A., Basu, S. S. & Zarrine-Afsar, A. Breaking through the barrier: Regulatory considerations relevant to ambient mass spectrometry at the bedside. Clin. Lab. Med. 41, 221\u2013246. https:\/\/doi.org\/10.1016\/j.cll.2021.03.004 (2021).","journal-title":"Clin. Lab. Med."},{"key":"33064_CR40","unstructured":"Fiorante, A. V. et al. A. Non-subjective diagnosis of lymphoma, glioma and metastatic carcinoma on intrasurgical timescales to optimize resection strategies. Submitted (2025)."},{"key":"33064_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2217\/17460875.3.3.273","volume":"3","author":"E Bieberich","year":"2008","unstructured":"Bieberich, E. Ceramide signaling in cancer and stem cells. Future Lipidol. 3, 273\u2013300. https:\/\/doi.org\/10.2217\/17460875.3.3.273 (2008).","journal-title":"Future Lipidol."},{"key":"33064_CR42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1172\/JCI89914","volume":"127","author":"KM Havas","year":"2017","unstructured":"Havas, K. M. et al. Metabolic shifts in residual breast cancer drive tumor recurrence. J. Clin. Invest. 127, 2091\u20132105. https:\/\/doi.org\/10.1172\/JCI89914 (2017).","journal-title":"J. Clin. Invest."},{"key":"33064_CR43","doi-asserted-by":"publisher","first-page":"e0137204","DOI":"10.1371\/journal.pone.0137204","volume":"10","author":"YY Jung","year":"2015","unstructured":"Jung, Y. Y., Kim, H. M. & Koo, J. S. Expression of lipid Metabolism-Related proteins in metastatic breast cancer. PLoS One. 10, e0137204. https:\/\/doi.org\/10.1371\/journal.pone.0137204 (2015).","journal-title":"PLoS One"},{"key":"33064_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-030-65768-0_9","volume":"1311","author":"J Salazar","year":"2021","unstructured":"Salazar, J. & Le, A. The heterogeneity of liver cancer metabolism. Adv. Exp. Med. Biol. 1311, 127\u2013136. https:\/\/doi.org\/10.1007\/978-3-030-65768-0_9 (2021).","journal-title":"Adv. Exp. Med. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33064-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33064-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:15:34Z","timestamp":1781626534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33064-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33064"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33064-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AZA is a co-inventor of \u2018soft ionization\u2019 utilized in this study and is consultant with Point Surgical Inc. with financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3198"}}